Results 31 to 40 of about 69,629 (300)

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease

Therapeutic Advances in Chronic Disease, 2019
Background: Inhaled levodopa may quickly resolve off periods in Parkinson’s disease. Our aim was to determine the pharmacokinetics and tolerability of a new levodopa dry-powder inhaler.
Marianne Luinstra, Wijnand Rutgers, Teus van Laar, Floris Grasmeijer, Anja Begeman, Valmira Isufi, Luc Steenhuis, Paul Hagedoorn, Anne de Boer, Henderik W. Frijlink   +9 more
doaj   +1 more source

Effects of levodopa on gut bacterial antibiotic resistance in Parkinson’s disease rat

Frontiers in Aging Neuroscience, 2023
The second most prevalent neurodegenerative ailment, Parkinson’s disease (PD), is characterized by both motor and non-motor symptoms. Levodopa is the backbone of treatment for PD at the moment.
Shuo Sheng, Xianwei Li, Shuo Zhao, Changqing Zheng, Feng Zhang, Feng Zhang, Feng Zhang   +6 more
doaj   +1 more source

Structural MRI Correlates of Episodic Memory Processes in Parkinson's Disease Without Mild Cognitive Impairment. [PDF]

, 2015
BackgroundChanges in episodic memory are common early in Parkinson's disease (PD) and may be a risk factor for future cognitive decline. Although medial temporal lobe (MTL) memory and frontostriatal (FS) executive systems are thought to play different ...
Filoteo, J Vincent, Harrington, Deborah L, Litvan, Irene, Pirogovsky-Turk, Eva   +3 more
core   +2 more sources

Impact of initial treatment on future symptoms and quality of life in Parkinson's disease

Chinese Journal of Contemporary Neurology and Neurosurgery, 2022
Objective To explore the effects of different initial drug treatment on motor symptoms, cognitive function and quality of life in patients with Parkinson's disease (PD).
LI Yu⁃wang, DONG Meng, CHEN Xue⁃jiao, WANG Min, LI Xin, CHEN Lei   +5 more
doaj   +1 more source

Criteria for the diagnosis of corticobasal degeneration [PDF]

, 2013
Current criteria for the clinical diagnosis of pathologically confirmed corticobasal degeneration (CBD) no longer reflect the expanding understanding of this disease and its clinicopathologic correlations.
Armstrong, Melissa J, Bak, Thomas H, Bhatia, Kailash P, Borroni, Barbara, Boxer, Adam L, Dickson, Dennis W, Grossman, Murray, Hallett, Mark, Josephs, Keith A, Kertesz, Andrew, Lang, Anthony E, Lee, Suzee E, Litvan, Irene, Miller, Bruce L, Reich, Stephen G, Riley, David E, Tolosa, Eduardo, Tröster, Alexander I, Vidailhet, Marie, Weiner, William J   +19 more
core   +1 more source

Expanding the spectrum of impulse control disorders in Parkinson's disease: the phenomenology of sweet craving [PDF]

, 2013
Thesis (M.A.)--Boston UniversityBackground: The recognized spectrum of impulse control disorders in Parkinson’s disease (PD) includes pathologic gambling, hypersexuality, compulsive buying, and binge eating, and is commonly related to exposure to ...
Brown, Caitlin Harrington
core   +1 more source

Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. [PDF]

, 2015
In Alzheimer disease, the gap between excellence of diagnostics and efficacy of therapy is wide. Despite sophisticated imaging and biochemical markers, the efficacy of available therapeutic options is limited.
Alessandro eStefani, Alessandro eStefani, Atticus H Hainsworth, Claudio eLiguori, Enrica eOlivola, Giacoma eAngileri, Mariangela ePierantozzi, Salvatore eGalati, Valentina eSaviozzi, Vincenza eD’Angelo   +9 more
core   +3 more sources

Lessons Learned From a Delayed‐Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Freezing of gait (FOG) in people with Parkinson's disease (PwPD) is debilitating and has limited treatments. Modafinil modulates beta/gamma band activity in the pedunculopontine nucleus (PPN), like PPN deep brain stimulation. We therefore tested the hypothesis that Modafinil would improve FOG in PwPD.
Tuhin Virmani, Lakshmi Pillai, Reid D. Landes, Aliyah Glover, Shannon Doerhoff, Jennifer Kleiner, Mitesh Lotia, Rohit Dhall, Edgar Garcia‐Rill   +8 more
wiley   +1 more source

Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia

Neurobiology of Disease, 2016
Ras homolog enriched in striatum (Rhes) is a small GTP-binding protein that modulates signal transduction at dopamine receptors, and also activates mammalian target of rapamycin complex 1 (mTORC1). Rhes binding to mTORC1 is hypothesized to play a role in
Alberto Brugnoli, Francesco Napolitano, Alessandro Usiello, Michele Morari   +3 more
doaj   +1 more source

Prescribing patterns and determinants for elderly patients with Parkinson's disease in Japan: a retrospective observational study using insurance claims databases

Frontiers in Neurology, 2023
BackgroundThis study aimed to determine real-world prescribing patterns and determinants for Japanese patients with Parkinson's disease (PD), with a focus on patients ≥75 years.MethodsThis was a retrospective, observational, longitudinal study of ...
Morinobu Seki, Yayoi Kawata, Ayako Hayashi, Masaki Arai, Shinji Fujimoto   +4 more
doaj   +1 more source